

## Curriculum Vitae

### Personal information

First name / Surname

**Guido Cavaletti**

Addresses

University of Milano-Bicocca, via Cadore 48, I-20900, Monza (Italy)

Telephone

+39 02 6448 8039

E-mail

guido.cavaletti@unimib.it

Nationality

Italian

Date of birth

27/02/1959

Gender

Male

Identification codes

ORCID: 0000-0003-4128-2406; SCOPUS: 7004360275;  
RESEARCHERID (WOS): AAA-7063-2022

### Occupational field

#### Work experience

Date

2015 - ongoing

Occupation or position held

Professor of Human Anatomy and Head of the Experimental Neurology Unit

Name and address of employer

University of Milano-Bicocca, Milano

Type of business or sector

University - Research

Date

2001-2015

Occupation or position held

Associate professor of Human Anatomy

Name and address of employer

University of Milano-Bicocca, Milano

Type of business or sector

University - Research

Dates

1998 – ongoing

Occupation or position held

Senior consultant neurologist and Head of the Neuroimmunology Unit

Name and address of employer

Fondazione IRCCS San Gerardo dei Tintori, Monza

Type of business or sector

Hospital – Clinical assistance and Research

Dates

1990 - 1998

Occupation or position held

Consultant neurologist

Name and address of employer

San Gerardo General Hospital, Monza

Type of business or sector

Hospital – Clinical assistance

#### Main services

Dates

2025 -

Occupation or position held

Vice-Rector

Name and address of employer

University of Milano-Bicocca, Milano

Type of business or sector

University - Research

Dates

2025 - 2025

Occupation or position held

Member of the Board of Directors

Name and address of employer

University of Milano-Bicocca, Milano

Type of business or sector

University - Research

Dates

2023 - ongoing

Occupation or position held

Member of the Board of Directors

Name and address of employer

Fondazione IRCCS San Gerardo dei Tintori, Monza

Type of business or sector

Hospital – Clinical assistance and Research

Date Occupation or position held Name and address of employer Type of business or sector	2018 - 2025 Vice-Rector for Research University of Milano-Bicocca, Milano University - Research																		
Date Occupation or position held Name and address of employer Type of business or sector	2018 – ongoing Chair of the Toxic Neuropathy Consortium Peripheral Nerve Society Scientific society - Research																		
Date Occupation and position held Name of society Type of business or sector	2015 - 2020 Member of the Board of Directors Associazione Italiana per lo Studio del Sistema Nervoso Periferico Scientific society – Research																		
Date Occupation or position held Name of society Type of business or sector	2015 - 2018 Deputy Director, School of Medicine and Surgery University of Milano-Bicocca, Milano University – Research																		
Date Occupation or position held Name of society Type of business or sector	2014 - 2019 Deputy Director, Milan Center for Neuroscience University of Milano-Bicocca, Milano University - Research																		
Date Occupation or position held Name of society Type of business or sector	2013 - 2015 President Associazione Italiana per lo Studio del Sistema Nervoso Periferico Scientific society – Research																		
Date Occupation or position held Name of society Type of business or sector	2010 – 2015/ex officio 2018-ongoing Member of the Board of Directors Peripheral Nerve Society Scientific society – Research																		
<b><u>Personal skills and competences</u></b>																			
Mother tongue	Italian																		
Other language Self-assessment European level (*)	English																		
<table border="1" data-bbox="628 1597 1422 1753"> <thead> <tr> <th colspan="2">Understanding</th> <th colspan="2">Speaking</th> <th colspan="2">Writing</th> </tr> <tr> <th>Listening</th> <th>Reading</th> <th>Spoken interaction</th> <th>Spoken production</th> <th colspan="2"></th> </tr> </thead> <tbody> <tr> <td>C2</td> <td>C2</td> <td>C2</td> <td>C2</td> <td>C2</td> <td>C2</td> </tr> </tbody> </table>		Understanding		Speaking		Writing		Listening	Reading	Spoken interaction	Spoken production			C2	C2	C2	C2	C2	C2
Understanding		Speaking		Writing															
Listening	Reading	Spoken interaction	Spoken production																
C2	C2	C2	C2	C2	C2														
(*) Common European Framework of Reference for Languages																			
<b><u>Awards</u></b>  2020 Alan J Gebhart Prize for Excellence in Peripheral Nerve Research, awarded by the International Peripheral Nerve Society (Baltimore, MD)																			

<p><b><u>Editorial activity and Commissions of Trust</u></b></p>	<p><b>Editorial Activity</b></p> <ul style="list-style-type: none"> <li>- Associate Editor, Journal of the Peripheral Nervous System (John Wiley &amp; Sons)</li> <li>- Editorial Board Member of Experimental Neurology (Elsevier), Medicinal Chemistry (Bentham Science), Current Drugs Safety (Bentham Science), Toxics (MDPI)</li> </ul> <p><b>Commission of Trust</b></p> <ul style="list-style-type: none"> <li>- Managing Committee - Member and President of the Scientific Training Program Committee – SYRA3 EU COST Action, 2013 – 2017</li> <li>- Panel Member – European Synchrotron Radiation Facility (Grenoble, F), 2009-2015</li> <li>- Member of the CME Subcommittee – European Federation of Neurological Societies, 2002 - 2005</li> <li>- Grant referee for Swiss League Against Cancer, Cancer Research UK, Slovenian Research Council, French INSERM, Singapore National Research Council</li> <li>- Career Development Reviewer: Columbia University (NY); University of Sidney; University of Maryland (MD), University of Rochester (NY), Hospital Universitari de Bellvitge (Barcelona)</li> </ul>
<p><b><u>Conference organization and invited presentations</u></b></p>	<p><b>Conference organization</b></p> <ul style="list-style-type: none"> <li>- Member of the Local Organizing Committee of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) 2025 meeting (Milano, 2025)</li> <li>- President of the International Symposium on Personalised Medicine in Multiple Sclerosis (Milano, 2017) and of the Congress of the Associazione Italiana per lo Studio del Sistema Nervoso Periferico (Monza, 2022).</li> <li>- Member of the Scientific Committee of the Peripheral Nerve Society meetings in Miami (2022) and of the virtual editions 2020 and 2021.</li> <li>- Member of the Organizing Committee of the Peripheral Nerve Society meetings in Lucca (2005) and Genoa (2019)</li> </ul> <p><b>Selected Invited Lectures</b></p> <p>Besides several International meetings, invited lectures at meetings organized by the US National Cancer Institute, National Institute of Health, Food and Drug Administration, American Society for Clinical Oncology, American Academy of Neurology, European Neurology Society/European Federation of Neurological Societies (currently European Academy of Neurology), European Association for Clinical Oncology, and International Association for the Study of Pain.</p>
<p><b><u>Competitive grants (PI or co-PI only)</u></b></p>	<p>2023 – ongoing: AdvanCed Technologies for Human-centrEd Medicine (ANTHEM) – MINISTERO DELL’UNIVERSITA’ E DELLA RICERCA</p> <p>2023 – ongoing: Understanding and targeting CHEMOtherapy-related neuroTOXicity (CHEMOTOX) – MINISTERO DELL’UNIVERSITA’ E DELLA RICERCA (PI)</p> <p>2021 – ongoing: HDACi: the Columbus's egg in improving cancer treatment and reducing neurotoxicity?- FONDAZIONE AIRC PER LA RICERCA SUL CANCRO</p> <p>2020 – 2024: NanoCosPha - Infrastruttura Regionale Lombarda - Nanotecnologie per la medicina personalizzata e i trattamenti di salute e cura estetica - REGIONE LOMBARDIA</p> <p>2019 – 2024: IMMUN-HUB - Sviluppo di nuove molecole di seconda generazione per immunoterapia oncologica - REGIONE LOMBARDIA</p>

<p><b><u>Main clinical and preclinical research interests</u></b></p> <p><b><u>Main international collaborations</u></b></p>	<p>2018 – 2024: Identificazione di polimorfismi genici e alterazioni epigenetiche per lo sviluppo di nuovi approcci farmacologici nel trattamento della neuropatia da oxaliplatino in pazienti con carcinoma coloretale - AGENZIA REGIONALE DI SANITA' DELLA TOSCANA</p> <p>2018 – 2023: Mechanisms of anti-tubulin activity of anticancer drugs and their relevance to neurotoxicity - THOMPSON FOUNDATION AT COLUMBIA UNIVERSITY OF NEW YORK</p> <p>2017 – 2023: Pathogenesis of Chemotherapy-Induced Peripheral Neurotoxicity (Pa-CIPN) - - MINISTERO DELL'UNIVERSITA' E DELLA RICERCA</p> <p>2016 – 2018: Radiation-enhanced metal-based chemotherapy in the treatment of solid tumors - FONDAZIONE AIRC PER LA RICERCA SUL CANCRO</p> <p>2015 – 2016: Studio pre-clinico dei meccanismi di tossicità dei trattamenti di chemioterapia anti-tumorale - FONDAZIONE BANCA DEL MONTE DI LOMBARDIA</p> <p>2013 – 2015: Understanding the pathogenesis of oxaliplatin-induced peripheral neurotoxicity - FONDAZIONE CARIPLO</p> <p>2012 – 2014: Diabetic peripheral neuropathy: relationship between neuroactive steroids and myelin lipid synthesis - FONDAZIONE CARIPLO</p> <p>2009-2010: Studio pre-clinico dei meccanismi di tossicità di farmaci antineoplastici e valutazione di possibili trattamenti neuroprotettivi - FONDAZIONE BANCA DEL MONTE DI LOMBARDIA</p> <p>2009 – 2011: Studio pilota per determinare il contributo dei neutrofili nello sviluppo di malattia in due modelli animali per la sclerosi multipla che mimano la forma acuta e recidivante-remittente di malattia - FONDAZIONE ITALIANA SCLEROSI MULTIPLA</p> <p>2009 – 2011: Network Enabled Drug Design - REGIONE LOMBARDIA</p> <p>2007 – 2010: Progetto di ricerca finalizzata dal titolo: Mediatori Endogeni ed Esogeni per contrastare i danni indotti da farmaci oncologici - MINISTERO DELLA SALUTE</p> <p>2004 – 2005: Neuropatia periferica da farmaci antineoplastici: indagine dei meccanismi di azione e valutazione di possibili strategie di neuroprotezione - FONDAZIONE BANCA DEL MONTE DI LOMBARDIA</p> <p>Toxic, metabolic, and inflammatory neuropathies; neuroimmunology and multiple sclerosis; innovative drug-and radiation-based anticancer treatments; drug delivery; advanced histopathology</p> <p><b>Academic</b></p> <p>Prof. A. Hoke/Prof. DR. Cornblath, Johns Hopkins University, Baltimore (MD)</p> <p>Prof. F. Bartolini, Columbia University, New York (NY)</p> <p>Prof. A. Sparreboom, Ohio State University, Columbus (OH)</p> <p>Prof. S. Dorsey, University of Maryland, Baltimore (MD)</p> <p>Prof. J.S. Gewandter, University of Rochester, Rochester (NY)</p> <p>Prof. S. Park, University of Sidney, Sydney, (Australia)</p> <p>Prof. E. Smith, University of Alabama, Birmingham (AL)</p> <p>Dr. A. Argyriou, Patras University Hospital, Patras (Greece)</p> <p>Prof. J Bruna, Universitat de Barcelona (Spain)</p> <p><b>Industrial</b></p> <p>Johnson &amp; Johnson, Pfizer, Roche, Novartis, Merck &amp; CO, UCB, Mundipharma, Helsinn, Grunenthal, Italfarmaco, Kedrion, Nitto, Kyowa, Algo Tx, NuraBio, Metys, Pledpharma, Augustine Tx</p>
---	---

<p><b><u>Patents</u></b></p>	<ol style="list-style-type: none"> <li>1. DELTA-2-TUBULIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR PERIPHERAL NEUROPATHY - WO2019108835A1 • 2019-06-06 • UNIV COLUMBIA [US]</li> <li>2. METHODS AND MATERIALS FOR TREATING NEUROTOXICITY WO2021067697A1 • 2021-04-08 • CAVION INC [US]</li> <li>3. SUBSTITUTED VINYL PIPERAZINE-PIPERIDINE UREA DERIVATIVES AS ANTICANCER AGENTS - WO2023057097A1-2023-04-13 • UNUV PAVIA/UNIV MILANO-BICOCCA [I]</li> </ol>
<p><b><u>Latest clinical trials</u></b></p>	<ul style="list-style-type: none"> <li>-Coordinator or participant in several spontaneous and sponsored clinical trials, in particular on pharmacological neuroprotection from the neurotoxic effects of anticancer chemotherapy.</li> <li>-Coordinator of an international network of Oncology and Neurology Centers involved in studies on the peripheral neurotoxicity of antineoplastic drugs (CI-PeriNomS Study Group) and of the largest international study on chemotherapy-induced neuropathy (International CIPN Assessment and Validation Study (ICAVS), ClinicalTrials.gov Identifier: NCT04633655).</li> <li>-Principal Investigator of the Algo Tx-sponsored clinical trial “A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of ATX01 (Topical Amitriptyline Hydrochloride 10% and 15% w/w) in Comparison to Placebo, in Cancer Survivor Adult Patients With Chemotherapy-induced Peripheral Neuropathy (CIPN)” (ClinicalTrials.gov) Identifier: NCT05593614)</li> <li>-Local PI of the CAPTIVATE trial to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy</li> </ul>
<p><b><u>Publications and metrics</u></b></p>	<p>&gt;400 Full Papers (Scopus), 8 Book Chapters  H index 76 (Scopus) – Citations&gt;19.000 (Scopus)</p> <p>Full list of publication at:  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=cavaletti+g">http://www.ncbi.nlm.nih.gov/pubmed/?term=cavaletti+g</a></p>

Pursuant to Article 13, Act 675/96 (Privacy Law), I hereby agree to the handling of my personal data.

Monza, Nov 1<sup>st</sup> 2025